سعر اورنيداز 500مجم 3 اقراص 2022

Ornidazole 500 mg tablets, 3 (Ornidaz, Chemipharm), a 5-nitroimidazole antiprotozoal/antibacterial.

• Urogenital trichomoniasis (Trichomonas vaginalis) in women and men, including asymptomatic carriers; partner treatment recommendedPopulation: AdultsFederal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium
• Intestinal and extra-intestinal amoebiasis (Entamoeba histolytica) and giardiasis (Giardia intestinalis)Population: Adults and children over 12 yearsFederal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium
• Continuation of treatment of anaerobic infections started parenterallyPopulation: AdultsFederal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium

• Reported (mostly rare, very rare or of unknown frequency): nausea, vomiting, upper abdominal pain; dizziness, somnolence, headache, asthenia, tremor, ataxia, coordination disorders, syncope, convulsions, confusion, taste disturbance, altered consciousness, peripheral neuropathy; transient haematological changes (leucopenia, agranulocytosis, aplastic anaemia, thrombocytopenia); anaphylactic shock; mood disorders; bronchospasm; hepatitis and abnormal liver tests; angioedema, rash, urticaria, fixed drug eruption; arthralgia; vaginal Candida superinfection.International label, same formulation · Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium

• Hypersensitivity to nitroimidazoles or to any excipient.International label, same formulation · Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium

• With high-dose and/or prolonged treatment (>10 days), regular clinical and laboratory tests including liver function are recommended; with a history of blood disorders or high-dose/prolonged treatment, monitor the white cell count.International label, same formulation · Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium
• May aggravate existing candidiasis; stop treatment in case of ataxia, vertigo or mental confusion; avoid driving if dizziness or somnolence occur.International label, same formulation · Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium
• Avoid alcohol because of the risk of a disulfiram-like reaction.International label, same formulation · Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium

• Alcohol and alcohol-containing medicinesDisulfiram-like reaction (flushing, redness, vomiting, tachycardia); combination not recommended.Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium
• Oral anticoagulants (e.g. warfarin)Anticoagulant activity may be increased; increased monitoring (INR).Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium
• Fluorouracil (and tegafur, capecitabine)Increased fluorouracil toxicity due to reduced clearance.Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium

• Insufficient data on excretion in milk; a risk to the infant cannot be excluded; Tiberal must not be used during breastfeeding.International label, same formulation · Federal Agency for Medicines and Health Products (FAGG-AFMPS), Belgium

• Ornidazole: Same mechanism as other nitroimidazoles; active against anaerobic Gram-negative bacteria (Bacteroides, Clostridium, Fusobacterium), anaerobic cocci, Trichomonas vaginalis, Entamoeba histolytica and Giardia intestinalis; inactive against Candida albicans (Belgian SmPC).